Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial

P. Drenko, M. Kacer, L. Kielberger, T. Vlas, O. Topolcan, R. Kucera, T. Reischig

. 2023 ; 25 (5) : e14150. [pub] 20230919

Language English Country Denmark

Document type Randomized Controlled Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24001137

Grant support
CZ.02.1.01/0.0/0.0/16_019/0000787 Charles University Cooperatio Program
00669806 Faculty Hospital in Pilsen
BBMRI-CZ: Biobank network

BACKGROUND: Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. A considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule. METHODS: In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the difference in the rate of a positive antibody response (SARS-CoV-2 IgG ≥10 AU/ml) between one and two booster doses at 1 month after the final booster dose. RESULTS: A positive humoral response was observed in 36 (62%) patients receiving two booster doses and in 28 (44%) patients receiving one booster dose (odds ratio [OR], 2.10, 95% confidence interval [CI], 1.02-4.34, p = .043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p = .009). The number of patients with positive virus neutralizing antibody (VNA) levels was numerically higher with two booster doses compared to one booster dose, but without statistical significance (66% vs. 50%, p = .084). There was no significant difference in positive seroconversions rate and antibody levels between mRNA-1273 and BNT162b2. CONCLUSION: A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001137
003      
CZ-PrNML
005      
20240213094115.0
007      
ta
008      
240109s2023 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/tid.14150 $2 doi
035    __
$a (PubMed)37724748
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Drenko, Petr $u Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0009000161384146
245    10
$a Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial / $c P. Drenko, M. Kacer, L. Kielberger, T. Vlas, O. Topolcan, R. Kucera, T. Reischig
520    9_
$a BACKGROUND: Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. A considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule. METHODS: In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the difference in the rate of a positive antibody response (SARS-CoV-2 IgG ≥10 AU/ml) between one and two booster doses at 1 month after the final booster dose. RESULTS: A positive humoral response was observed in 36 (62%) patients receiving two booster doses and in 28 (44%) patients receiving one booster dose (odds ratio [OR], 2.10, 95% confidence interval [CI], 1.02-4.34, p = .043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p = .009). The number of patients with positive virus neutralizing antibody (VNA) levels was numerically higher with two booster doses compared to one booster dose, but without statistical significance (66% vs. 50%, p = .084). There was no significant difference in positive seroconversions rate and antibody levels between mRNA-1273 and BNT162b2. CONCLUSION: A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a vakcíny proti COVID-19 $x škodlivé účinky $7 D000086663
650    _2
$a vakcína BNT162 $7 D000090982
650    _2
$a vakcína firmy Moderna proti COVID-19 $7 D000090983
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    12
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a protilátky virové $7 D000914
650    _2
$a imunoglobulin G $7 D007074
650    _2
$a příjemce transplantátu $7 D066027
650    _2
$a mRNA vakcíny $7 D000087503
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kacer, Martin $u Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Kielberger, Lukas $u Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000321494364
700    1_
$a Vlas, Tomas $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $1 https://orcid.org/0000000248356511 $7 jx20090623009
700    1_
$a Topolcan, Ondrej $u Department of Immunochemistry Diagnostics, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $1 https://orcid.org/000000016622390X $7 jn20000402383
700    1_
$a Kucera, Radek $u Department of Immunochemistry Diagnostics, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $u Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000227392302 $7 jo2016919265
700    1_
$a Reischig, Tomas $u Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/000000025404598X
773    0_
$w MED00005143 $t Transplant infectious disease $x 1399-3062 $g Roč. 25, č. 5 (2023), s. e14150
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37724748 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094112 $b ABA008
999    __
$a ok $b bmc $g 2049625 $s 1210831
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 5 $d e14150 $e 20230919 $i 1399-3062 $m Transplant infectious disease $n Transpl Infect Dis $x MED00005143
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000787 $p Charles University Cooperatio Program
GRA    __
$a 00669806 $p Faculty Hospital in Pilsen
GRA    __
$p BBMRI-CZ: Biobank network
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options